8 Coupons
may 17, 2018 -- the fda has approved the first in a new class of migraine drugs that aim to fight painful .
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv). .
the youngest claimant was aged 20, and the eldest aged 89, while the average policy duration at claim stage was 10 years. .
.